Skip to main content

Table 2 Pretherapeutic Staging of 30 Patients with Indolent Lymphoma using WB-DWIBS/STIR and 18F-FDG-PET/CT

From: Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients

  

Reference Staging*

 
  

Stage IE

Stage II

Stage III

Stage IIIS

Stage IIIE

Stage IV

Kappa [95% CI] §

WB-DWIBS/STIR (R1)

Stage IE

10

0

0

0

0

0

0.96 [0.88–1.00]

Stage II

0

5

0

0

0

0

Stage III

0

0

6

0

0

0

Stage IIIS

0

0

1

2

0

0

Stage IIIE

0

0

0

0

1

0

Stage IV

0

0

0

0

0

5

WB-DWIBS/STIR (R2)

Stage IE

10

0

0

0

0

0

0.96 [0.88–1.00]

Stage II

0

5

0

0

0

0

Stage III

0

0

6

0

0

0

Stage IIIS

0

0

1

2

0

0

Stage IIIE

0

0

0

0

1

0

Stage IV

0

0

0

0

0

5

18F-FDG-PET/CT (R1)

Stage 0

1

0

0

0

0

0

0.92 [0.80–1.00]

Stage IE

9

0

0

0

0

0

Stage II

0

4

0

0

0

0

Stage III

0

0

7

0

0

0

Stage IIIS

0

1

0

2

0

0

Stage IIIE

0

0

0

0

1

0

Stage IV

0

0

0

0

0

5

18F-FDG-PET/CT (R2)

Stage IE

10

0

0

0

0

0

0.96[0.88–1.00]

Stage II

0

4

0

0

0

0

Stage III

0

0

7

0

0

0

Stage IIIS

0

1

0

2

0

0

Stage IIIE

0

0

0

0

1

0

Stage IV

0

0

0

0

0

5

  1. §The pretherapeutic staging does not reflect bone marrow involvement of lymphoma
  2. *Data are numbers of patients. R1 = observer 1, R2 = observer 2, WB-DWIBS/STIR = whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery magnetic resonance imaging, 18F-FDG-PET/CT = 18F-fluorodeoxyglucose-positron emission tomography-computed tomography
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us